Keynote 158 cervical11/8/2023 ![]() Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. Schilder RJ, Blessing JA, Morgan M, Mangan CE, Rader JS. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Muderspach LI, Blessing JA, Levenback C, Moore JL Jr. The role of chemotherapy in the management of carcinoma of the cervix. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. ![]() Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Real-world experience of pembrolizumab monotherapy in patients with recurrent or persistent cervical cancer: a Korean multi-center retrospective study (KGOG1041). Ĝhoi MC, Kim YM, Lee JW, Lee YJ, Suh DH, Lee SJ, et al. Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies. ![]() ğreites-Martinez A, Santana N, Arias-Santiago S, Viera A. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Ğisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. Archives of Pathology & Laboratory Medicine. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. Ĝhung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. ğrenel JS, Le Tourneau C, O’Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, et al. Improved survival with bevacizumab in advanced cervical cancer. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Journal of the National Comprehensive Cancer Network. ![]() NCCN guidelines insights: cervical cancer, version 1.2020. Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, et al. Prediction of cancer incidence and mortality in Korea, 2022. Jung KW, Won YJ, Kang MJ, Kong HJ, Im JS, Seo HG. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |